Mantle cell lymphoma (MCL) is an uncommon non-Hodgkinlymphoma that is generally considered incurable. Covalent BTK inhibitors (cBTKi)are the cornerstone of treatment for relapsed or refractory (R/R) MCL, buttreatment options are limited and prognosis is poor after cBTKi failure.Pirtobrutinib is a non-covalent BTK inhibitor that has demonstrated excellentefficacy and safety and represents an important new treatment in the evolvingtreatment landscape of R/R MCL. This review will provide an overview of the therapeuticlandscape of R/R MCL, characteristics of pirtobrutinib, and efficacy and safetydata of pirtobrutinib in R/R MCL from pivotal clinical trials. PubMed and majorhematology conference proceedings were searched to identify relevant studiesinvolving pirtobrutinib. For patients with R/R MCL that has progressed aftertreatment with cBTKi, pirtobrutinib is an important and efficacious treatmentthat confers favorable outcomes. In the post-cBTKisetting, when chimeric antigen receptor (CAR) T-cell therapy is not availableor feasible, pirtobrutinib is the preferred treatment for R/R MCL. How tosequence or combine pirtobrutinib with CAR T-cell therapy and other availableor emerging therapies requires further investigation. Future studies shouldalso explore the role of pirtobrutinib inearlier lines of therapy for MCL.